<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132027</url>
  </required_header>
  <id_info>
    <org_study_id>BA0859003</org_study_id>
    <nct_id>NCT01132027</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Tacrolimus Capsules, 5 mg of Dr. Reddys's Laboratories Limited Under Non-Fasting Conditions</brief_title>
  <official_title>An Open Label, Two Way Crossover, Balanced, Single Dose, Comparative Evaluation of Relative Bioavailability of Tacrolimus Capsules 5 mg With That of 'Prograf' Capsules 5 mg in Healthy Subjects Under Non-fasting Conditions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the relative bioavailability study of tacrolimus
      capsules 5 mg with prograf capsules 5 mg in healthy, adult, human subjects under non-fasting
      conditions and to monitor safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomized, two period, two treatment, two sequence, crossover, balanced,
      single dose, comparative evaluation of relative bioavailability of tacrolimus capsules 5 mg
      with that of 'prograf' capsules 5 mg in healthy adult human subjects under non-fasting
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability study based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prograf Capsules of Astellas Pharma US, Inc.,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Capsules</intervention_name>
    <description>Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_label>Prograf Capsules</arm_group_label>
    <other_name>Prograf capsules of Astellas Pharma US, Inc.,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subjects should be healthy human between 18 and 45 years.

          2. The subjects should be screened within 21 days prior to the administration of first
             dose of the study drug.

          3. The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter.

          4. The subjects should be able to communicate effectively with study personnel.

          5. The subjects should be able to give written informed consent to participate in the
             study.

             If subject is a female volunteer and

          6. Is of child bearing potential practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condoms,foams,
             jellies, diaphragm, intrauterine device (IUD), or abstinence.

          7. Is postmenopausal for at least 1 year.

          8. Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy has been performed on the subject).

        Exclusion Criteria:

          1. The subjects who have a history of allergic responses to tacrolimus or other related
             drugs.

          2. The subjects who have significant diseases or clinically significant abnormal findings
             during screening, medical history, physical examination, laboratory evaluations, ECG,
             and X-ray recordings.

          3. The subjects who have any disease or condition which might compromise the
             haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central
             nervous system, diabetes, psychosis or any other body system.

          4. The subjects who have a history or presence of bronchial asthma.

          5. The subjects who have used enzyme-modifying drugs within 30 days prior to receiving
             the first dose of study medication.

          6. The subjects who have history of drug dependence, recent history of alcoholism or of
             moderate alcohol uses.

          7. The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or
             more than or equal to 20 biddies per day or those who cannot refrain from smoking
             during study period.

          8. The subjects with a history of difficulty with donating blood or difficulty in
             accessibility of veins.

          9. The subjects who have donated 1 unit (350 ml / 450 ml) blood within 90 days prior to
             receiving the first dose of study medication.

         10. The subjects who have a positive hepatitis screen (include subtypes A, B, C and E).

         11. The subjects who have a positive test result for HIV antibody and / or syphilis
             (RPR/VDRL).

         12. The subject who receives an investigational product, or has participated in a drug
             research study within a period of 90 days prior to the first dose of the study
             medication application.

         13. Female volunteers demonstrating a positive pregnancy screen.

         14. Female volunteers who are currently breast-feeding.

         15. Female volunteers not willing to use contraception during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Simran Sethi, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>BA Research India Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BA Research India Limited</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ramesh Mullangi/Director - R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability, crossover, tacrolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

